, 2005 [91]   Reported to AZD1480 mouse inhibit growth and proliferation of medullary thyroid carcinoma

cells Du et al., 2006 [92]   siRNA approach     Reported o downregulate Survivin and diminish radioresistance in pancreatic cancer cells Kami et al., 2005 [93]   Reported to inhibit proliferation and induce apoptosis in SPCA1 and SH77 human lung adenocarcinoma cells Liu et al., 2011 [94]   Reported to suppress Survivin expression, inhibit cell proliferation and enhance apoptosis in SKOV3/DDP ovarian cancer cells Zhang et al., 2009 [95]   Reported to enhance the radiosensitivity of human non-small cell lung cancer cells Yang et al., 2010 [96] Other IAP antagonists Small molecules antagonists     Cyclin-dependent kinase inhibitors and Hsp90 inhibitors and gene therapy attempted in targeting Survivin in cancer therapy Pennati et al., 2007 [97]   Cyclopeptidic Smac mimetics 2 and 3 report to bind to XIAP

and cIAP-1/2 and restore the activities of caspases- 9 and 3/-7 inhibited by XIAP Sun et al., 2010 [98]   SM-164 reported to enhance TRAIL activity by concurrently targeting XIAP and cIAP1 Lu et al., 2011 [99] Targeting caspases     Caspase-based drug therapy Apoptin reported to selectively induce apoptosis in malignant but not normal cells Rohn et al, 2004 [100]   Small molecules caspase activators reported to lower mTOR inhibitor the activation threshold of caspase or activate caspase, contributing to an increased drug sensitivity of cancer cells Philchenkov et al., 2004 [101] Caspase-based gene therapy Human caspase-3 gene therapy used in addition to etoposide treatment in an AH130 liver tumour model reported to induce extensive apoptosis and

reduce tumour volume Yamabe et al., 1999 [102]   Gene transfer of constitutively active caspse-3 into HuH7 human hepatoma cells reported to selectively induce apoptosis Cam et al., 2005 [103]   A recombinant adenovirus carrying immunocaspase 3 reported to exert enough anticancer effect in hepatocellular carcinoma in vitro and in vivo Li et al., 2007 [104] 4.1 Targeting the Bcl-2 family of buy ARN-509 proteins Some potential treatment strategies used in targeting the Bcl-2 family of proteins include the use of therapeutic agents to inhibit the Bcl-2 family of anti-apoptotic proteins or the silencing of the upregulated anti-apoptotic proteins or genes involved. 4.1.1Agents that target the Bcl-2 family of proteins One good example of these agents is the drug oblimersen sodium, which is a Bcl-2 antisence oblimer, the first agent targeting Bcl-2 to enter clinical trial. The drug has been reported to show chemosensitising effects in combined treatment with conventional anticancer drugs in chronic myeloid leukaemia patients and an improvement in survival in these patients [66, 67]. Other examples included in this category are the small molecule inhibitors of the Bcl-2 family of proteins.